Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice by unknown
RESEARCH ARTICLE Open Access
Recombinant domains III of Tick-Borne
Encephalitis Virus envelope protein in
combination with dextran and CpGs induce
immune response and partial protectiveness
against TBE virus infection in mice
Anna S. Ershova1,2,3*, Olga A. Gra1, Alexander M. Lyaschuk1, Tatyana M. Grunina1, Artem P. Tkachuk1,
Mikhail S. Bartov1, Darya M. Savina1, Olga V. Sergienko1,2, Zoya M. Galushkina1, Vladimir P. Gudov1,
Liubov I. Kozlovskaya4, Ivan S. Kholodilov4, Larissa V. Gmyl4, Galina G. Karganova4, Vladimir G. Lunin1,2,
Anna S. Karyagina1,2,3 and Alexander L. Gintsburg1
Abstract
Background: E protein of tick-borne encephalitis virus (TBEV) and other flaviviruses is located on the surface of the
viral particle. Domain III of this protein seems to be a promising component of subunit vaccines for prophylaxis of
TBE and kits for diagnostics of TBEV.
Methods: Three variants of recombinant TBEV E protein domain III of European, Siberian and Far Eastern subtypes
fused with dextran-binding domain of Leuconostoc citreum KM20 were expressed in E. coli and purified. The native
structure of domain III was confirmed by ELISA antibody kit and sera of patients with tick-borne encephalitis.
Immunogenic and protective properties of the preparation comprising these recombinant proteins immobilized on
a dextran carrier with CpG oligonucleotides as an adjuvant were investigated on the mice model.
Results: All 3 variants of recombinant proteins immobilized on dextran demonstrate specific interaction with
antibodies from the sera of TBE patients. Thus, constructed recombinant proteins seem to be promising for TBE
diagnostics. The formulation comprising the 3 variants of recombinant antigens immobilized on dextran and CpG
oligonucleotides, induces the production of neutralizing antibodies against TBEV of different subtypes and
demonstrates partial protectivity against TBEV infection.
Conclusions: Studied proteins interact with the sera of TBE patients, and, in combination with dextran and CPGs,
demonstrate immunogenicity and limited protectivity on mice compared with reference “Tick-E-Vac” vaccine.
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Background
Tick-borne encephalitis (TBE) presents a threat for a
public health in different countries [1]. TBEV is divided
into 3 subtypes: European, Siberian, and Far-Eastern,
and the Siberian subtype is the most widespread in
Russia [2], nevertheless TBEV strains of different sub-
types are serologically related closely [3]. Vaccination
with one of the currently used purified inactivated TBE
vaccines derived from cell cultures is the main prophy-
lactic tool. European TBE vaccines are prepared from
European TBEV strains, and Russian – from Far-Eastern
ones. Long history and wide geography of TBE vaccines
and tiny percent of incidence among vaccinated use
proves their efficacy regardless the original subtype [4].
Technological process of inactivated vaccine preparation
includes accommodation of large amounts of highly
neurovirulent virus stock, which complicates the vaccine
production site and elaborates biosafety and biosecurity
measures. Recombinant protein subunit vaccines do not
pose this kind of threat. Additionally, full vaccination
scheme includes 3 primary injections with booster re-
vaccinations every 3–5 years. Vaccination of the popula-
tion living in endemic areas, is a burden to the federal
budget. Therefore, there is a need in development of
new low cost subunit vaccines with a safe production
process that could cause prolonged immunity without
additional revaccinations.
E protein of TBEV and other flaviviruses is located on
the surface of the viral particle. E protein mediates the
binding of virus to the host cell receptors and the penetra-
tion of virus into the cell [5, 6], and is a main target for
host immune system antibodies [7, 8]. E protein ectodo-
main consists of 3 domains: I, II and III. Antibodies
against domain III are found in the sera of patients and la-
boratory animals after infection or vaccination [9]. TBEV
E protein domain III has an Ig-fold structure and can fold
independently from the rest of the protein molecule
[10]. Domain III sequences are conservative (80 – 95 %
amino acid sequence identity) among tick-borne flavi-
viruses [10, 11]. Above mentioned properties make
TBEV E protein domain III a promising component for
development of subunit vaccines against 3 TBE sub-
types and kits for diagnostics of TBEV [12].
Immunogenic potency of TBEV E protein domain III is
significantly lower than potency of the whole virion or
soluble E protein [13], however, it can be increased by
addition of adjuvants. It has been shown that immuno-
genic potency of E protein domain III of Dengue virus can
be significantly increased by addition of CpG oligonucleo-
tides [14]. Similar effects were shown for the E protein
domain III of West Nile virus in combination with CpG
oligonucleotides [15] or Freund’s incomplete adjuvant [16].
Immobilization of a protein on the carrier results in a
longer circulation of this protein in organism, and as a
result, in more intense immune response [14]. On the
other hand, immobilization of the protein on the carrier
also can make it convenient component of a diagnostic
system.
In this work the immunogenic properties and pro-
tective efficacy of compositions comprising 3 variants
of recombinant protein which includes domain III of
TBEV E protein fused with the dextran-binding domain
immobilized on dextran and CpG oligonucleotides were
studied. We found that all 3 variants of TBEV E protein
domain III immobilized on dextran can specifically
interact with the sera of patients with TBE. Preparation
comprising the recombinant TBEV E protein domain
III and CpG oligonucleotides induces the production of
neutralizing antibodies, but demonstrates limited pro-
tectivity as compared with Tick-E-Vac vaccine.
Methods
Cells and viruses
Porcine embryo kidney (PEK) cells (obtained from
Mechnikov Moscow Research Institute of vaccines and
sera, 1959–1965) were maintained at 37 °C in medium
199 (FSUE IPVE, Russia) supplemented with 5 % fetal
bovine serum (Gibco ThermoFisher Scientific, USA).
TBEV strains Absettarov (GenBank ID AF091005),
isolated in the Leningrad region in 1951; Vasilchenko
(GenBank ID AF069066), isolated in the Novosibirsk
region in 1969; Sofjin (GenBank ID KC8506252), isolated
in Far East in 1937, were from the laboratory virus collec-
tion of the Chumakov Institute of poliomyelitis and viral
encephalitides. Viruses were stored as aliquots of 10 %
infected mouse brain suspensions or infected PEK cells
cultural fluids at -70 °C.
Reference vaccine
“Tick-E-Vac” tissue culture, purified, concentrated, inac-
tivated, sorbed TBE vaccine (FSUE Manufacture of Bac-
terial and Viral Preparations of Chumakov Institute of
Poliomyelitis & Viral Encephalitides, Russia), from the
TBEV strain Sofjin, 0.25 ml suspension for intramuscular
injection for vaccination of children from 1 to 16 years
of age, lot 005, was used in the present work.
Sera
Sera from patients with acute TBE were kindly provided
by Dr. V.V. Pogodina and sera of healthy donors were
from laboratory collection of the Chumakov Institute of
poliomyelitis and viral encephalitides. Sera samples
were collected at Russian hospitals with informed consent
from patients or their legal representatives and trans-
fered to the Chumakov IPVE as a part of routine TBE
diagnostics.
Hyperimmune ascites fluid (HIAF) was obtained in mice
after 3 immunizations with the TBEV strain Ek-328.
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Selection of amino acid sequences of TBEV E protein
domain III and multiple alignment
Complete amino acid sequences of TBEV E protein
domain III (397 entries) available on 25th of February,
2014 were selected from RefSeq Data Base using
BLAST (e = 1e-63). Multiple alignment (see Additional
file 1) was constructed using COBALT tool [17].
Amino acid sequences of TBEV E protein domain III
selected based on analysis of multiple alignment (see
Results) for construction of recombinant proteins















Amino acid residues different in genetic subtypes are
marked by bold and italic.
Construction of recombinant plasmids for expression of
chimeric TBEV E protein domain III/DBD2 gene
The synthetic genes, corresponding to the sequences of
3 variants of TBEV E protein domain III listed in above
section were cloned in the earlier constructed plasmid
pL125, which includes dextran binding domain from
Leuconostoc citreum KM20 and Gly-Ser spacer [18]. As a
result, 3 recombinant plasmids (pDBD2-D3S, pDBD2-
D3E and pDBD2-D3F) were constructed, each coding
for chimeric gene composed of nucleotide sequence of
dbd2 gene, Gly-Ser spacer and nucleotide sequence of
1of 3 variants of TBEV E protein domain III. Molecular
mass of recombinant proteins calculated according to
amino acid sequence was 28.1 kDa.
Expression procedure
The producing strains E. coli M15 [Rep4, pDBD2-D3S],
E. coli M15 [Rep4, pDBD2-D3E] and E. coli M15 [Rep4,
pDBD2-D3F] were grown in liquid LB medium with
kanamycin (25 μg/mL) and ampicillin (150 μg/mL)
using 0.2 mM of isopropyl-β-D-thiogalactoside (IPTG)
for induction of protein synthesis. Biomass yield was
approximately 5 g/L.
Isolation and purification of recombinant proteins
Protein purification was performed using Sephadex
G200 (ChemBioMed, Russia) chromatography with urea
gradient elution and dialysis against PBS buffer at 25 °C
overnight. Purity of DBD2-D3S, DBD2-D3E, DBD2-D3F
antigen samples was higher than 95 %, as was deter-
mined by sodium dodecyl sulfate-gel electrophoresis on
12 % polyacrylamide gels [19].
Immobilization of proteins on dextran
Protein samples were diluted to 0.25 mg/ml of PBS, equal
volume of 100 mg/ml suspension of Dextran 500 (Phar-
macosmos, Denmark) was added, and the samples were
incubated at +25 °C for 1 hour with constant mixing.
ELISA
Several modifications of ELISA were used during the
present work:
To evaluate the ability of the protein preparations to
interact with the anti-TBEV antibodies we used 1)
“VectoTBE-Antigen” (Vector Best, Russia) according
to the manufacturer’s protocol; and 2) ELISA with
standard technique by the following scheme: 1st layer
– investigated protein preparation, 2nd layer – sera of
TBE patients, 3rd layer – HRP-conjugated anti-human
antibodies (Fermentas ThermoFisher Scientific, USA);
sera of non-vaccinated donors from non-endemic
territories was used as a negative control. Antibody
titers in the sera of TBE patients were determined
using “VectoTBE-IgG” (VectorBest, Russia) according
to the manufacturer’s protocol.
To evaluate the antibody titers in immunized mice sera
we used 3) ELISA performed using standard technique by
the following scheme: 1st layer – antigen (AG), 2nd layer –
dilutions of analyzed sera, 3rd layer – HRP-conjugated
anti-mouse antibodies (Fermentas ThermoFisher Scientific,
USA). AG was prepared from concentrated cell culture
supernatant as described earlier [20]. Normal antigen from
non-infected cells was used as a negative control. AG and
normal AG were equilibrated by protein content.
Sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and Western blot analysis
The protein samples were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
in 12 % PAAG in Protean II EF cell (Bio-Rad, Russia).
Separated protein bands were transferred onto a PVDF-
membrane (GE Healthcare, USA). The membrane was
blocked with 5 % skim milk in PBS overnight at 4 °C.
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TBEV proteins were detected using sera of TBE patients
or control sera as a primary antibody and HRP-conjugated
goat anti-human antibodies (Fermentas ThermoFisher
Scientific, USA) as a secondary antibody dissolved in 5 %
skim milk in PBS with 0.05 % Tween-20. The bands were
visualized by reaction with DAB substrate.
Fifty percent plaque reduction neutralization test
(PRNT50)
PRNT50 was performed as described earlier [21]. Briefly,
sequential dilutions of sera were prepared in 199
medium on Earle solution with addition of 2 % FBS
(Gibco ThermoFisher Scientific, USA). Equal volume of
virus suspension, containing 40−50 PFU, were added to
each sera dilution. Virus + sera were incubated at 37 °C
for 1 h. Then, virus + sera suspensions were added to
PEK cells, and incubated at 37 °C for 1 h with gentle
shaking for virus adsorption. Then, cells were overlaid
with 5 ml of 1 % bactoagar (Difco, USA) on Earle solu-
tion containing 7.5 % FBS and 0.015 % neutral red. After
incubation at 37 °C on day 7 plaques were counted.
Every experiment included appropriate controls – nega-
tive and positive sera with known antibodies titer. The
antibodies titer was calculated according to modified
Reed-and-Muench method.
Immunogenic potency in mice
Recombinant proteins were combined into following
preparations:
3DIII + Dex: Combination of equimolar quantities of 3
recombinant proteins DBD2-D3S, DBD2-D3E and
DBD2-D3F (containing 20 μg of each antigenic domain
(D3S, D3E, and D3F) immobilized on 25 mg of Dextran
500 (Pharmacosmos, Denmark).
3DIII + AD: Combination of 3DIII + Dex with CpG-
oligonucleotides. Thionilated oligonucleotides CPG B-
class specific for mouse TLR9 were synthesized on a 12
column DNA synthesizer Polygen (Polygen GmbH,
Germany) using modified protocols with tetra-
ethylthiuram disulfide (TEDT) as sulfurizing reagent
[22]. S-thionilated product was purified by reverse
phase HPLC (Gilson, USA) using XBridge OST C-18
2.5 μm (4.6 x 50 mm) column (Waters, USA). Mobile
phase: A: 0.1 M TEAA, B: Acetonitrile/0.1 M TEAA, 20/
80 (v/v) and gradient: 35 − 65 % B in 24 min (7–13 %
ACN, 0.25 % ACN per minute), desalted by NAP-10 (GE
Healthcare, USA) and lyophilized (Labconco, USA).
BALB/c mice of 22–24 g (Stolbovaya branch of Scien-
tific Centre of biomedical technologies, Moscow region,
Russia) were randomized by weight into groups of 10
mice and were immunized subcutaneously (s/c) 3 times
with studied preparations (0.5 ml, containing 20 μg of
each recombinant protein (D3S, D3E, and D3F), 25 mg
of Dextran 500 and 0.25 mg of each CpG (ODN 1585
and ODN 1826)) with 7 days period or 2 times with
Tick-E-Vac (0.2 human dose in 0.5 ml) with 7 days
period. Control group was injected 3 times with 0.5 ml
of physiological saline with 7 days period. Sera were
collected 1–4 weeks after the first vaccination.
Protective efficacy in mice
BALB/c mice of 12–14 g (Stolbovaya branch of Scientific
Centre of biomedical technologies, Moscow region,
Russia) were randomized by weight into groups of 10 mice
and s/c immunized several times (for details see Results)
with 0.5 ml of sequential dilutions of studied protein prep-
arations or “Tick-E-Vac” with 7 day period between vacci-
nations. Control animals were injected with 0.5 ml of
physiological saline. Mice were intraperitoneally (i/p) chal-
lenged with 200LD50 TBEV strain Vasilchenko (0.3 ml)
7 day after the last vaccination. Mice were observed for
clinical symptoms and weighted every day for 21 day after
the challenge. Mice were assumed as ill if showing clinical
symptoms (generalized intoxication, paresis, paralysis) or
if losing weight 1.5 g or more per 3 days or longer.
Three mice from each group were bled 1 day prior
and 1 day after the challenge. Sera were stored at -80 °C
until use.
Procedures on animals were performed according to
Directive 2010/63/EU and Appendix A to the European
Convention ETS No. 123.
Statistical analysis
Exact Fisher’s test was used for comparison of survival
in the groups of mice. P < 0.05 was considered to indi-
cate a statistically significant result.
Log-Rank test was used for the statistical analysis of
both survival and illness curves. P < 0.01 was considered
to indicate a statistically significant result.
Results
Estimation of TBEV E protein domain III variability
To select sequences of TBEV E protein domain III, which
could cause immunity to most TBEV strains, we evaluated a
variety of known amino acid sequences and its possible im-
pact on domain III interaction with neutralizing antibodies.
Ecker and co-authors [23] have shown that amino
acid residues at positions 313, 317, 331, and 349 dif-
fer in the 3 main TBEV subtypes. Our analysis of 398
available up to date amino acid sequences of TBEV E
protein domain III showed that these sequences are
highly conservative (>96 % similarity). Meanwhile
amino acid residues at position 349 are not specific
for any of TBEV subtypes, and the amino acid resi-
dues at position 313, 317 and 331 are mainly different
for different subtypes of TBEV (see Table 1).
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According to combinations of amino acid sequences in
313, 317 and 331 positions the Siberian subtype splits
into 2 groups that correspond to Asian (A-T-T) and
European (T-T-T) topovariants defined by Karan and
co-authors [24].
Data presented in Table 1 demonstrate that according
to combinations of amino acid residues at positions 313,
317 and 331 the majority (92 %) of the known TBEV E
protein sequences can be attributed to 1 of 3 known
TBEV subtypes.
To evaluate the potential involvement of these amino
acid residues in the interaction of TBEV E protein do-
main III with neutralizing antibodies we analyzed the
contact area in spatial structure of complex presented in
Fig. 1a. All 3 residues at positions 313, 317 and 331 are
located on the protein surface and thus can be accessible
for interaction with antibodies. However, in the structure
of the virion different regions of domain III can have
different accessibility to antibodies. The most well char-
acterized are surface epitopes of E protein domain III of
West Nile virus [26–28]. It was shown that neutraliz-
ing antibodies to E protein domain III (murine and hu-
man) primarily interact with the region of DIII-lr (DIII
lateral surface), formed by L1 and L2 loops (see Fig. 1a)
[26, 27]. Thus, the sequences of L1 and L2 loops may
be of special interest for selection of sequences of anti-
genic determinants for cloning.
However, as it is seen in Fig. 1b, both loops are highly
conservative. The sequence LTYTMCDKTKF in the L1
loop is typical for 92 % of 398 analyzed sequences, the se-
quence FSGPK-PCRIPV in the L2 loop is typical for 98 %
of 398 analyzed sequences. Therefore, the most common
variants of these sequences were selected for cloning.
In complex with neutralizing antibody all 3 different
amino acid residues in various TBEV subtypes, especially
residues at positions 313 and 331, that are directly
adjoint to the L1 and L2 loops, can influence the inter-
action of neutralizing antibodies with E protein domain
III (see Fig. 1a). Thus, we selected all 3 variants of TBEV
E-protein domain III corresponding to European (T-A-
T), Siberian (Asian topovariant) (A-T-T) and Far-Eastern
(T-I-A) subtypes for cloning. It should be noted that the
sequence of European subtype (T-A-T) with threonine
residues in 313 and 331 positions also covers the
European topovariant of the Siberian subtype.
Cloning, expression and purification of recombinant TBEV
E protein domain III variants
Three recombinant plasmids: pDBD2-D3S, pDBD2-D3E,
and pDBD2-D3F containing chimeric genes composed
of dextran binding domain DBD2 from Leuconostoc
citreum KM20 (DBD2), nucleotide sequence coding for
10 amino acid residues spacer including 5 Gly-Ser
repeats, and nucleotide sequence of 1 of variant of
TBEV E protein domain III: of Siberian, European or
Far-Eastern subtypes, were constructed (Fig. 2a).
Production of recombinant DBD2-D3S, DBD2-D3E
and DBD2-D3F proteins determined by electrophoresis
was about 20–30 % of total cell protein (Fig. 2b). After
purification recombinant proteins were electrophoretic-
ally homogenous and were stored as 2 mg/ml solutions
(Fig. 2c). For immunological properties study the pro-
teins were immobilized on dextran (see Material and
Methods section).
Evaluation of ability of recombinant preparations to
interact with anti-TBEV antibodies
Firstly, preparations of recombinant proteins DBD2-D3S,
DBD2-D3E and DBD2-D3F, immobilized on dextran, were
investigated as antigen in “VectoTBE-Antigen” ELISA kit.
All preparations with protein concentrations 5–20 μg/ml
showed ability to interact with monoclonal anti-TBEV
antibodies from the kit.
Secondly, we performed ELISA using recombinant
proteins DBD2-D3S, DBD2-D3E and DBD2-D3F, immo-
bilized on dextran, as first layer sorbed on the ELISA
plate against sera of TBE patients from different territor-
ies with different TBEV subtypes prevalent (positive for
antibodies against TBEV according to “VectoTBE-IgG”
ELISA kit) and healthy people (negative for anti-TBEV
antibodies). Thirdly, recombinant proteins DBD2-D3S,
DBD2-D3E and DBD2-D3F, immobilized on dextran,
Table 1 Representation of amino acid residues in three
positions of different TBEV subtypes E protein
Amino acid residue and its
position in the E protein
Number of strains of different
TBEV subtypesa
Total
313 317 331 E FE S ND
A T T 67 19 86
T T T 1 28 7 36
T V T 3 2 5
A I T 2 2 4
T I T 2 2
T I A 54 1 56b 111
T A A 1 1
T T A 4 5c 9
T A S 2 6 8
T A T 55 80 135
Total number of strains 61 58 100 179 397
a)E is European subtype, FE is Far-Eastern subtype, S is Siberian subtype, ND is
“not determined”, e.g. the subtype is not specified in amino acid sequence
annotation and in the corresponding article. The most common variants are
shown in bold, genotypes are listed according to the sequence authors
b)Strain 886-84, which was annotated as genotype 5 in [25], belongs to
this group
c)Strain 178-79, which was annotated as genotype 4 in [25], belongs to
this grou
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were analyzed in PAGE-Western-blot (WB) with the
same sera.
Dextran-binding domain itself was used as a nega-
tive control in WB; murine TBEV HIAF was used as
a positive control in WB and revealed specific band
of all studied recombinant proteins, but not DBD
(See Additional file 2: Table S1).
Recombinant proteins DBD2-D3S, DBD2-D3E and
DBD2-D3F, immobilized on dextran, did not interact
with the sera of healthy donors in both ELISA and
WB. DBD2 did not interact with any sera in WB.
Recombinant proteins interacted with most of the
TBE patients sera in ELISA and revealed target band
of 28kD in WB.
Therefore, recombinant proteins DBD2-D3S, DBD2-
D3E and DBD2-D3F, immobilized on dextran, can spe-
cifically interact with antibodies against TBEV.
Immunogenic potency on mice
Mice were immunized 3 times with studied prepara-
tions (3DIII + Dex and 3DIII + AD) or 2 times with
reference vaccine “Tick-E-Vac” with 7 days period.
Control group was injected 3 times with saline with 7 days
period. Sera were collected 1–4 weeks after the first vac-
cination and analyzed in ELISA individually and in
PRNT50 against strains Absettarov, Vasilchenko, Sofjin of
3 TBEV subtypes in pools. Data are presented in Table 2.
Fig. 2 Scheme of recombinant plasmids and analysis of recombinant genes’ expression and proteins purification in 12 % SDS-PAGE (Laemmli, 1970).
a. Recombinant plasmids pDBD2-DIII. b, c. Coomassie blue-stained 12 % SDS/PAGE gels of cell extracts (b) and purified proteins (c). Target proteins are
marked by black arrows. b. Lanes 1, 3, 6, 9 – extracts of bacterial cells before IPTG induction: E. coli M15 [pRep4], E. coli M15 [pRep4, pDBD2-D3S], E. coli
M15 [pRep4, pDBD2-D3E], E. coli M15 [pRep4, pDBD2-D3F]. Lanes 4, 5 – cell extracts of E. coli M15 [pRep4, pDBD2-D3S], 7, 8 – of E. coli M15 [pRep4,
pDBD2-D3E], 10 – of E. coli M15 [pRep4, pDBD2-D3F] after 2 h IPTG induction. Lane 11 - page ruler unstained molecular mass marker («Fermentas»,
Lithuania). c. Coomassie blue-stained 12 % SDS/PAGE gels of purified recombinant proteins DBD2-D3S (line 1), DBD2-D3E (line 2) and DBD2-D3F (line
3). Line 4 – molecular mass marker Thermo Scientific PageRuler Unstained Low Range Protein Ladder Part No. 26632
Fig. 1 Cartoon representation of spatial structure (a) and alignment of amino acid sequences (b) of E protein domain III regions involved in the
interaction with neutralizing antibodies. a. Superimposition of TBEV E protein domain III structure from 1svb PDB entry (DIIIE) with structure of
West Nile Virus E protein domain III (is not shown) in complex with neutralizing E16 antibody Fab (1ztx) (Ab E16). Fragment of neutralizing E16
antibody is shown in gray, TBEV E protein domain III is shown in dark gray, the rest part of E protein is shown in light gray, amino acid residues
313, 317 and 331 are shown by black spheres. b. Alignment of all different variants of L1 and L2 loops and adjacent 313 and 331 residues.
Alignment is highlighted by gray scale fill according to percent of identity. Numbers of amino acid residues forming L1 and L2 loops are
designated above alignment (numbering is according to 1svb structure), 313 and 331 residues are designated below alignment. TBEV subtypes
are designated on the right as follows: FE is Far-Eastern, Sa is Siberian (Asian topovariant), Se is Siberian (European topovariant), E is European
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According to ELISA antibody titer in mice sera in-
creased in later terms after the vaccinations with both
preparations, 3DIII + Dex and 3DIII + AD, which was
expected.
Starting from the first week after 2 immunizations
antibodies induced by both recombinant protein prep-
arations and “Tick-E-Vac” were detected in both tests.
“Tick-E-Vac” caused neutralizing antibodies in higher
titers and against strains of different subtypes. Re-
combinant protein preparations caused significant rise
of neutralizing antibodies against strains of Siberian
or Far-Eastern subtypes, but antibodies against strain
Absettarov of European TBEV subtype rise on the second
week, and then decrease to undetectable levels. Neverthe-
less, 3DIII + AD caused faster and more effective antibody
response then 3DIII + Dex. Protein preparation 3DIII +
AD was chosen for protective efficacy study in mice.
Protective efficacy in mice
We evaluated protective efficacy of studied preparation
3DIII + AD against TBEV strain Vasilchenko, as a repre-
sentative of the most abundant in Russia Siberian sub-
type, in mice compared to reference vaccine “Tick-E-
Vac” according to 2 schemes: standard and prime-boost.
In standard scheme mice were immunized 3 times with
3DIII + AD with 7 days period and challenged 7 days
after the last vaccination. In prime-boost scheme mice
were immunized first with “Tick-E-Vac” and then 2
times with 3DIII + AD with 7 days period and challenged
7 days after the last vaccination. Reference vaccination
of mice was performed 2 times with “Tick-E-Vac” with
7 days period and challenged 7 days after the last vaccin-
ation. To determine the minimal immunization dose
groups of mice were vaccinated with series of prepara-
tions dilutions (1, 1/10. 1/32, 1/100, 1/320). Control
group was injected 3 times with saline with 7 days period
and challenged 7 days after the last injection. Mice were
observed for clinical symptoms and weighed 21 days after
the challenge. Sera from 3 mice of each group were
collected right before and 24 h after the challenge. Sera
pools were studied in ELISA and PRNT50 against TBEV
strains Vasilchenko, Absettarov and Sofjin. Experimental
schemes and test results are summarized in Table 3.
With standard scheme 1 dose of 3DIII + AD protected
50 % mice from 100LD50 of TBEV strain Vasilchenko
(see Fig. 3a). However, all survived mice showed clinical
symptoms of infection (see Fig. 3b, Additional file 2:
Table S2). One dose of reference vaccine Tick-E-Vac
showed 100 % protectivity, with no mice showing TBE
clinical symptoms. With prime-boost scheme com-
bined use of “Tick-E-Vac” and 3DIII + AD provided
survival of 100 % mice, although 40 % mice in this
scheme showed mild symptoms of infection (see Fig. 3,
Additional file 2: Table S2).
Table 2 Antibody titers in sera of mice, immunized with studied preparations and the “Tick-E-Vac”
Preparation ELISAa PRNT50 TBEV strain (subtype)
Vasilchenko (Siberian) Sofjin (Far-Eastern) Absettarov (European)
1 week after the 1st immunization
3DIII + Dex 1:10 1:10 1:20 <1:10
3DIII + AD <1:10 <1:10 1:20 <1:10
Tick-E-Vac <1:10 <1:10 1:10 <1:10
1 week after the 2nd immunization
3DIII + Dex 1:70 <1:10 <1:10 <1:10
3DIII + AD 1:500 <1:10 1:30 1:30
Tick-E-Vac n/sb 1:200 1:250 1:70
1 week after the 3d immunization for 3DIII + Dex and 3DIII + AD;
2 weeks after the 2nd immunization for Tick-E-Vac
3DIII + Dex 1:3000 1:10 1:25 <1:10
3DIII + AD 1:2500 1:20 1:20 <1:10
Tick-E-Vac n/s 1:20 1:170 1:30
2 weeks after the 3d immunization for 3DIII + Dex and 3DIII + AD;
3 weeks after the 2nd immunization for Tick-E-Vac
3DIII + Dex 1:4000 1:10 1:20 <1:10
3DIII + AD 1:16000 1:20 1:40 <1:10
Tick-E-Vac n/s 1:20 1:90 1:30
aELISA was performed by the scheme 3) (see Materials and Methods)
bn/s – non-specific interaction. Samples of sera of mice immunized with “Tick-E-Vac” showed high optical density in ELISA with both viral AG and negative control
AG, thus the interaction was not determined
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Vaccination with preparation dilutions allowed to de-
termine the minimal immunization dose. MID for 3DIII
+ AD was 0.5 ml (3*20 μg of the recombinant proteins)
and for “Tick-E-Vac” – 0.003 ml.
All preparations caused antibody response. Neutraliz-
ing antibody titers differed depending on the scheme
and TBEV serotype of challenging virus. The highest
titers showed prime-boost scheme against TBEV strain
Absettarov of European subtype.
Discussion
Analysis of currently available amino acid sequences of
TBEV E protein domain III showed that 92 % of the se-
quences belonging to 1 of 3 subtypes: European, Siberian
or Far Eastern, varied in 3 positions 313, 317 and 331. 8 %
of TBEV E protein domain III sequences cannot be attrib-
uted to any of the known subtypes according to these 3
diagnostic positions. There is a possibility that the poly-
morphisms in these positions are the result of recombin-
ation between TBE subtypes [29, 30]. The amino acid
residues at 313, 317 and 331 positions are on the surface
of TBEV E protein domain III (see Fig. 2a), and can
contribute to its interaction with the neutralizing anti-
bodies. Therefore, to study the immunogenic potency of
the recombinant TBEV E protein domain III we selected 3
variants of amino acid sequences corresponding to the 3
most common subtypes of TBEV. Similarity of the anti-
genic properties of recombinant TBEV E protein domain
III synthesized in E. coli to native TBEV E protein domain
III structure was showed by ELISA with a set of antibodies
to TBEV, as well as by Western-blot analysis demonstrat-
ing the interaction of recombinant proteins immobilized
on dextran with TBE patients sera. Thus, the constructed
recombinant antigens seem to be promising in terms of
the development of diagnostic kits for TBE.
Also we demonstrate that immunization with a prep-
aration containing TBEV E protein domain III induces
the formation of antibodies against TBEV in titers
dependent on the adjuvant composition. On the fourth
week after immunization with recombinant antigens
with addition of both dextran adjuvant and CpG oligo-
nucleotides the titer of antibodies was 4 times higher
than after immunization with a preparation containing
only dextran (Table 2).
The neutralization test (PRNT50) with 3 strains repre-
senting different TBEV subtypes showed increase in
neutralizing antibodies titers after immunization with
TBEV E protein domain III over time (see Table 3).
Nevertheless, the maximum serum dilution that neutral-
izes 50 % of the virus obtained after immunization with
a preparation containing TBEV E protein domain III in
all studied periods was lower than the one obtained after
immunization with a Tick-E-Vac vaccine containing
inactivated TBEV.
Data on PRNT50 are in good agreement with the
literature data on the immunogenic potency of domain
III of E glycoprotein of Dengue and West Nile flavi-
viruses. Chiang and co-authors [14] studied the immuno-
genic properties of genetically engineered vaccine for
prevention of Dengue fever. The investigated candidate
vaccine contained recombinant Dengue virus E protein
domain III as antigen and CpG oligonucleotides as adju-
vant. 6 weeks after the first immunization of BALB/c mice
with this preparation (30 μg of Dengue virus E protein
domain III in 1 dose) mean titer of serum neutralizing
50 % of the virus was 1:30. In another work 8 weeks after
immunization of mice with preparation containing
West Nile virus E protein domain III serum titer neu-
tralizing 50 % of the virus was 1:35 [13]. These results
are similar to our data on neutralizing activity of the
mice serum (see Table 3).
Table 3 Protective efficacy of 3DIII + AD and the “Tick-E-Vac” vaccine on mice upon standard and prime-boost schemes


















3DIII + AD 10 +a 3DIII + AD + + 1:4000 <1:10 1:50 <1:10 5c 0
Prime-boost scheme
Tick-E-Vac 10 + 3DIII + AD + + 1:3000 1:20 1:250 1:50 10c 6
Reference scheme
Tick-E-Vac 10 – Tick-E-Vac + + 1:1500 1:80 1:100 1:250 10c 10
Control
Saline 10 + Saline + + <1:500 <1:10 <1:10 <1:10 0 0
Mice were challenged with the TBEV strain Vasilchenko (Vas). Antibody titers against TBEV strains Vasilchenko, Absettarov (Abs) and Sofjin (Sof) were measured
a+mice were vaccinated; – mice were not vaccinated
bmice were intraperitoneally (i/p) challenged with 200LD50 TBEV strain Vasilchenko
cp < 0.05 compared to the control group (exact Fisher test)
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Protective properties of our preparation are also com-
parable with the literature data [16, 31], but lower than
of the whole-virion vaccine.
Therefore, the resulting formulation based on 3 variants
of recombinant TBEV E protein domain III immobilized
on dextran and CpG oligonucleotides (3DIII + AD)
possesses a certain immunogenic potential in comparison
to formulation without CpG (3DIII + Dex), see Table 2. It
induces the production of neutralizing antibodies at the
same level as similar preparations based on E protein
domain III of other flavivirus, but worse than whole-virion
Tick-E-Vac vaccine. As a result, further refinement of this
formulation is required so that it could be used for effect-
ive subunit TBE vaccine development.
One of the obvious ways to enhance the immunogenic
potency of the preparation is to include other TBEV pro-
teins [9] or additional fragments of TBEV E protein. This is
especially important due to the fact that, as it was recently
shown, the immune response to flavivirus infection differs
between mouse and human [10, 32]. In particular, the spe-
cificity of neutralizing antibodies induced after TBEV infec-
tion or vaccination differs between these 2 species [10].
Another direction of improvement of the preparation
is to optimize the adjuvant composition, since, as it is
shown by Chiang [14], the adjuvant composition has a
significant impact on the immunogenic potency and
protectivity of formulation containing E protein domain
III as antigen.
Another way to improve the immunogenic and pro-
tective properties of the preparation may be an
optimization of immunization schedule, including the
use of recombinant TBEV E protein domain III
based formulation for booster immunization after
immunization with whole-virion inactivated vaccine.
It was shown that a booster injection of E protein
domain III after immunization with inactivated virus
or by soluble protein results in considerable en-
hancement of the neutralizing capacity of the serum
in comparison with the double injection of inacti-
vated virus or soluble E protein [13]. Thus, the
optimization of immunization schedule can prolong
the immunity response against TBE and decrease the
number of re-vaccinations that would lower the
costs of re-vaccinations.
Fig. 3 Survival (a) and morbidity (b) curves. Tick-E-Vac means group of mice (n = 10) immunized with Tick-E-Vac by standard scheme; 3DIII + AD means
group of mice (n = 10) immunized with 3DIII + AD by standard scheme, Prime-boost means group of mice (n = 10) immunized with Tick-E-Vac and
3DIII + AD by prime-boost scheme. Group of mice (n = 10) immunized by saline was used as a control. Mice were assumed as ill if showing clinical
symptoms (generalized intoxication, paresis, paralysis) or if losing weight 1.5 g or more per 3 days or longer. Statistical significance was determined by
Log-rank test. * p < 0.01 compared with a control (saline), # p < 0.01 compared with Tick-E-Vac
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Conclusions
All 3 recombinant proteins comprising 3 variants of
TBEV E protein domain III immobilized on dextran can
specifically interact with the sera of patients with TBE.
Thus, constructed recombinant proteins are promising
for TBE diagnostics. It is also shown that the preparation
comprising the recombinant TBEV E protein domain III
immobilized on dextran and CpG oligonucleotides
induces the production of neutralizing antibodies, but
demonstrates limited protectivity as compared with Tick-
E-Vac vaccine and, thus, requires further optimization to
enhance immunogenic properties and protective capabil-
ity. Nevertheless, this approach could be used for new vac-
cines that could replace the existing vaccines at least on
the stage of boost vaccination, if not entirely.
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